Top Markets
#1 Derive Derive +33.82%
#2 Cross Cross +15.09%
#3 Geodnet Geodnet +13.37%
#4 Gama Token Gama Token +9.17%
#5 Talus Network Talus Network +8.96%
#6 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +7.42%
#7 Cap Cap +6.96%
#8 Audiera Audiera +5.78%
#9 OVERTAKE OVERTAKE +5.63%
#10 Ontology Gas Ontology Gas +5.54%
Coin of the day
Derive Derive
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Clasificación en acciones #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Precio por acción
$1.73
Última sincronización: 2025-06-17
Capitalización bursátil
$2.55M
Cambio (1 día)
-0.29%
Cambio (1 año)
0.00%
País
US
Comercio Eiger BioPharmaceuticals, Inc. (EIGR)

Categoría

Healthcare
Ganancias de Eiger BioPharmaceuticals, Inc. (EIGR)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Eiger BioPharmaceuticals, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Eiger BioPharmaceuticals, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE